BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune ...
(PR-inside.com) 40% objective response rate (ORR) as single agent in heavily pre-treated patients with advanced Cutaneous T-Cell Lymphoma (CTCL) Durable responses observed, including a complete response lasting over two years and ongoing 50% ORR in combination with KEYTRUDA® (pembrolizumab) Targeting TNFR2 drove robust…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


